Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 7/20/2026

1. BA
2. SPY
3. USO
4. RTX
5. AMC

6. NVDA
7. XFLT
8. GE
9. TRV
10. PSNL

Get Alerts HARP Hot Sheet

Price: $23.01 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences:

A panel discussion titled “Heavenly (anti)Bodies” at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 1:10 p.m. ET / 10:10 a.m. PT; and
A presentation at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 at 10:30 a.m. ET / 7:30 a.m. PT. A live webcast of the Canaccord presentation will be available from the Events and Presentations section of the company’s website at https://ir.harpoontx.com/events-and-presentations and will be archived there shortly after the event.

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Contacts:

Harpoon Therapeutics, Inc.Georgia ErbezChief Financial Officer650-443-7400[email protected]

Westwicke ICRRobert H. UhlManaging Director858-356-5932 [email protected]